Tags

Type your tag names separated by a space and hit enter

Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
J Emerg Med. 2004 Nov; 27(4):395-405.JE

Abstract

To compare the efficacy of sequential i.v. to p.o. moxifloxacin with ceftriaxone +/- azithromycin +/- metronidazole for the treatment of patients with community acquired pneumonia (CAP), a multi-centered, prospective, randomized, open label study was performed. CAP patients were randomized to moxifloxacin (400 mg/d-at least one i.v. dose) or ceftriaxone (at least one dose of 2 g i.v. q.d. followed by cefuroxime 500 mg p.o. b.i.d.) +/- azithromycin, +/- metronidazole (cephalosporin/macrolide control: CMC). The primary endpoint was clinical response at test-of-cure (TOC) visit. Bacteriological response at TOC was the secondary endpoint. Clinical cure was found in 83.3% (90/108) of moxifloxacin patients and 79.6% (90/113) of control patients. Microbiological responses were 81.8% (18/22) for moxifloxacin and 60.7% (17/28) for CMC patients. Drug-related adverse events occurred in 18.0% of moxifloxacin and 16% of CMC patients. It is concluded that i.v. to p.o. moxifloxacin is as effective as CMC for treatment of CAP and is a reliable alternative antimicrobial therapy.

Authors+Show Affiliations

Washington University, St. Louis, Missouri 63110, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15498622

Citation

Katz, Eric, et al. "Safety and Efficacy of Sequential I.v. to P.o. Moxifloxacin Versus Conventional Combination Therapies for the Treatment of Community-acquired Pneumonia in Patients Requiring Initial I.v. Therapy." The Journal of Emergency Medicine, vol. 27, no. 4, 2004, pp. 395-405.
Katz E, Larsen LS, Fogarty CM, et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med. 2004;27(4):395-405.
Katz, E., Larsen, L. S., Fogarty, C. M., Hamed, K., Song, J., & Choudhri, S. (2004). Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. The Journal of Emergency Medicine, 27(4), 395-405.
Katz E, et al. Safety and Efficacy of Sequential I.v. to P.o. Moxifloxacin Versus Conventional Combination Therapies for the Treatment of Community-acquired Pneumonia in Patients Requiring Initial I.v. Therapy. J Emerg Med. 2004;27(4):395-405. PubMed PMID: 15498622.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. AU - Katz,Eric, AU - Larsen,L Scott, AU - Fogarty,Charles M, AU - Hamed,Kamal, AU - Song,James, AU - Choudhri,Shurjeel, PY - 2003/04/03/received PY - 2003/11/19/revised PY - 2004/02/03/accepted PY - 2004/10/23/pubmed PY - 2005/4/22/medline PY - 2004/10/23/entrez SP - 395 EP - 405 JF - The Journal of emergency medicine JO - J Emerg Med VL - 27 IS - 4 N2 - To compare the efficacy of sequential i.v. to p.o. moxifloxacin with ceftriaxone +/- azithromycin +/- metronidazole for the treatment of patients with community acquired pneumonia (CAP), a multi-centered, prospective, randomized, open label study was performed. CAP patients were randomized to moxifloxacin (400 mg/d-at least one i.v. dose) or ceftriaxone (at least one dose of 2 g i.v. q.d. followed by cefuroxime 500 mg p.o. b.i.d.) +/- azithromycin, +/- metronidazole (cephalosporin/macrolide control: CMC). The primary endpoint was clinical response at test-of-cure (TOC) visit. Bacteriological response at TOC was the secondary endpoint. Clinical cure was found in 83.3% (90/108) of moxifloxacin patients and 79.6% (90/113) of control patients. Microbiological responses were 81.8% (18/22) for moxifloxacin and 60.7% (17/28) for CMC patients. Drug-related adverse events occurred in 18.0% of moxifloxacin and 16% of CMC patients. It is concluded that i.v. to p.o. moxifloxacin is as effective as CMC for treatment of CAP and is a reliable alternative antimicrobial therapy. SN - 0736-4679 UR - https://www.unboundmedicine.com/medline/citation/15498622/Safety_and_efficacy_of_sequential_i_v__to_p_o__moxifloxacin_versus_conventional_combination_therapies_for_the_treatment_of_community_acquired_pneumonia_in_patients_requiring_initial_i_v__therapy_ DB - PRIME DP - Unbound Medicine ER -